4//SEC Filing
Aunins John G. 4
Accession 0000899243-19-002137
CIK 0001609809other
Filed
Jan 28, 7:00 PM ET
Accepted
Jan 29, 6:51 PM ET
Size
9.6 KB
Accession
0000899243-19-002137
Insider Transaction Report
Form 4
Aunins John G.
CTO and EVP of Bioprocess Dev.
Transactions
- Award
STOCK OPTION (RIGHT TO BUY)
2019-01-25+60,000→ 60,000 totalExercise: $6.01Exp: 2029-01-24→ Common Stock (60,000 underlying) - Exercise/Conversion
RESTRICTED STOCK UNITS
2019-01-26−7,500→ 12,500 total→ Common Stock (7,500 underlying) - Exercise/Conversion
COMMON STOCK
2019-01-26+7,500→ 92,750 total
Footnotes (3)
- [F1]Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
- [F2]The option will vest as to 25% of the shares on January 25, 2020. The remainder of the shares will vest in 12 equal quarterly installments thereafter.
- [F3]These restricted stock units have vested and settled or will vest and settle as to 20% of the restricted stock units on January 26, 2018, 30% on January 26, 2019, and 50% on January 26, 2020.
Documents
Issuer
Seres Therapeutics, Inc.
CIK 0001609809
Entity typeother
Related Parties
1- filerCIK 0001643756
Filing Metadata
- Form type
- 4
- Filed
- Jan 28, 7:00 PM ET
- Accepted
- Jan 29, 6:51 PM ET
- Size
- 9.6 KB